{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 407806745
| IUPAC_name = ''N''-[(4-Methoxyphenoxy)carbonyl]-''N''-<nowiki/>{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}glycine
| image = Muraglitazar.svg
| width = 315

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Development terminated
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 331741-94-7
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 206044
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = W1MKM70WQI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05091
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 557580
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 178524

<!--Chemical data-->
| C=29 | H=28 | N=2 | O=7 
| molecular_weight = 516.54 g/mol
| smiles = CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IRLWJILLXJGJTD-UHFFFAOYSA-N
| synonyms = 2-[(4-Methoxyphenoxy)carbonyl-<nowiki>[[</nowiki>4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
}}

'''Muraglitazar''' (proposed tradename '''Pargluva''') is a dual [[PPAR agonist|peroxisome proliferator-activated receptor agonist]] with affinity to [[Peroxisome proliferator-activated receptor alpha|PPARα]] and [[Peroxisome proliferator-activated receptor gamma|PPARγ]].<ref>{{cite journal|last1=Waites|first1=CR|last2=Dominick|first2=MA|last3=Sanderson|first3=TP|last4=Schilling|first4=BE|title=Nonclinical Safety Evaluation of Muraglitazar, a Novel PPARα/γ Agonist|journal=Toxicological Sciences|date=13 August 2007|volume=100|issue=1|pages=248–58|doi=10.1093/toxsci/kfm193|pmid=17675651|url=http://toxsci.oxfordjournals.org/content/100/1/248.full.pdf|accessdate=9 November 2016}}</ref>

The drug had completed [[clinical trial#Phase III|phase III clinical trial]]s,<ref name="Kendall">{{cite journal|last1=Kendall|first1=DM|last2=Rubin|first2=CJ|last3=Mohideen|first3=P|last4=Ledeine|first4=JM|last5=Belder|first5=R|last6=Gross|first6=J|last7=Norwood|first7=P|last8=O'Mahony|first8=M|last9=Sall|first9=K|last10=Sloan|first10=G|last11=Roberts|first11=A|last12=Fiedorek|first12=FT|last13=DeFronzo|first13=RA|title=Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels with Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy|journal=Diabetes Care|date=May 2006|volume=29|issue=5|pages=1016–23|doi=10.2337/diacare.2951016|pmid=16644631|url=http://care.diabetesjournals.org/content/diacare/29/5/1016.full.pdf|accessdate=9 November 2016}}</ref> however in May, 2006  [[Bristol-Myers Squibb]] announced that it had discontinued  further development.<ref>{{cite web|title=Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes|url=http://www.prnewswire.com/news-releases/bristol-myers-squibb-announces-discontinuation-of-development-of-muraglitazar-an-investigational-oral-treatment-for-type-2-diabetes-56462702.html|publisher=PR Newswire from Bristol-Myers Squibb|accessdate=9 November 2016|date=May 18, 2006}}</ref>

Data on muraglitazar is relatively sparse due to the recent introduction of this agent. One double-blind randomized clinical trial<ref name="Kendall" /> comparing muraglitazar and [[pioglitazone]] found that the effects of the former were favourable in terms of [[high-density lipoprotein|HDL-C]] increase, decrease in total [[cholesterol]], [[apolipoprotein B]], [[triglyceride]]s and a greater reduction in [[Glycated hemoglobin|HbA<sub>1c</sub>]] ([[p-value|''p'']] <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of [[edema]] and [[heart failure]] and more weight gain compared to the pioglitazone group. A [[meta-analysis]] of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of [[myocardial infarction]], [[stroke]], [[transient ischemic attack]]s and congestive heart failure (CHF) when compared to placebo or pioglitazone.<ref>{{cite journal|last1=Nissen|first1=SE|last2=Wolski|first2=K|last3=Topol|first3=EJ|title=Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus|journal=Journal of the American Medical Association|date=23 November 2005|volume=294|issue=20|pages=2581–6|doi=10.1001/jama.294.20.joc50147|pmid=16239637|accessdate=9 November 2016}}</ref>

==References==
{{Reflist}}

{{Oral hypoglycemics}}
{{PPAR modulators}}

[[Category:Abandoned drugs]]
[[Category:Oxazoles]]
[[Category:Carbamates]]
[[Category:Phenol ethers]]
[[Category:PPAR agonists]]

{{gastrointestinal-drug-stub}}